KEYMED BIOSCIENCES INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 37.7 HKD | +5.90% |
|
+4.28% | -23.12% |
| Apr. 30 | Keymed Biosciences' Allergy Treatment NDA Accepted by NMPA | MT |
| Apr. 29 | Keymed Biosciences Allergy Drug Achieves Phase III Clinical Trial End Points | MT |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 7,864 | 12,600 | 12,348 | 9,086 | - | - |
| Enterprise Value (EV) 1 | 4,378 | 12,118 | 12,348 | 8,054 | 7,039 | 9,086 |
| P/E ratio | -1.16 x | -38.2 x | -32.6 x | -11.5 x | -12.9 x | -19.7 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 71.3 x | 126 x | 34.9 x | 81.4 x | 15.9 x | 7.23 x |
| EV / Revenue | 39.7 x | 121 x | 34.9 x | 72.1 x | 12.4 x | 7.23 x |
| EV / EBITDA | -10.9 x | -44.5 x | -43 x | -10.6 x | -10.3 x | -18.4 x |
| EV / FCF | -11.3 x | -17.8 x | - | -8.39 x | -8.46 x | -13 x |
| FCF Yield | -8.83% | -5.62% | - | -11.9% | -11.8% | -7.72% |
| Price to Book | 2.15 x | 3.74 x | - | 4.09 x | 6.2 x | 8.8 x |
| Nbr of stocks (in thousands) | 279,736 | 279,736 | 276,696 | 276,604 | - | - |
| Reference price 2 | 28.11 | 45.04 | 44.63 | 32.85 | 32.85 | 32.85 |
| Announcement Date | 3/29/22 | 3/17/23 | 3/26/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 110.3 | 100.1 | 354.1 | 111.7 | 569.8 | 1,256 |
| EBITDA 1 | - | -402.3 | -272.6 | -286.9 | -760.4 | -686.2 | -493.7 |
| EBIT 1 | - | -415.2 | -544.5 | -457.4 | -820.1 | -758 | -502.8 |
| Operating Margin | - | -376.55% | -544.15% | -129.18% | -734.34% | -133.03% | -40.02% |
| Earnings before Tax (EBT) 1 | -818.8 | -3,893 | -303.6 | -356.2 | -793 | -756 | -475.2 |
| Net income 1 | -818.6 | -3,887 | -308.1 | -359.4 | -794.6 | -705.6 | -467 |
| Net margin | - | -3,525.3% | -307.92% | -101.49% | -711.53% | -123.84% | -37.17% |
| EPS 2 | - | -24.17 | -1.180 | -1.370 | -2.865 | -2.540 | -1.671 |
| Free Cash Flow 1 | - | -386.4 | -680.8 | - | -959.4 | -832 | -701.4 |
| FCF margin | - | -350.44% | -680.33% | - | -859.09% | -146.03% | -55.83% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Announcement Date | 6/25/21 | 3/29/22 | 3/17/23 | 3/26/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 3,485 | 482 | - | 1,031 | 2,046 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -386 | -681 | - | -959 | -832 | -701 |
| ROE (net income / shareholders' equity) | - | -22.7% | -8.81% | - | -33.4% | -48.3% | -45.1% |
| ROA (Net income/ Total Assets) | - | -13% | -7.83% | - | -24.6% | -26.8% | -16.3% |
| Assets 1 | - | 29,902 | 3,933 | - | 3,231 | 2,633 | 2,872 |
| Book Value Per Share 2 | - | 13.10 | 12.00 | - | 8.030 | 5.300 | 3.730 |
| Cash Flow per Share 2 | - | -1.330 | -1.540 | - | -3.270 | -2.650 | -1.020 |
| Capex 1 | - | 172 | 279 | - | 201 | 101 | 99.4 |
| Capex / Sales | - | 155.79% | 278.65% | - | 179.68% | 17.67% | 7.91% |
| Announcement Date | 6/25/21 | 3/29/22 | 3/17/23 | 3/26/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
32.85
CNY
Average target price
53.98
CNY
Spread / Average Target
+64.34%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -23.12% | 1.26B | |
| +10.44% | 107B | |
| +0.82% | 106B | |
| +7.98% | 23.47B | |
| -13.89% | 21.9B | |
| -6.13% | 18.77B | |
| -37.26% | 17.85B | |
| -10.98% | 16.78B | |
| +8.67% | 14.41B | |
| +41.08% | 12.86B |
- Stock Market
- Equities
- 2162 Stock
- Financials Keymed Biosciences Inc.